Annual EBITDA
-$99.11 M
-$12.67 M-14.66%
31 December 2023
Summary:
Immunic annual earnings before interest, taxes, depreciation & amortization is currently -$99.11 million, with the most recent change of -$12.67 million (-14.66%) on 31 December 2023. During the last 3 years, it has fallen by -$50.18 million (-102.55%). IMUX annual EBITDA is now -2388.43% below its all-time high of $4.33 million, reached on 31 December 2011.IMUX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$25.68 M
-$2.90 M-12.73%
30 September 2024
Summary:
Immunic quarterly earnings before interest, taxes, depreciation & amortization is currently -$25.68 million, with the most recent change of -$2.90 million (-12.73%) on 30 September 2024. Over the past year, it has dropped by -$2.15 million (-9.13%). IMUX quarterly EBITDA is now -8726.12% below its all-time high of -$291.00 thousand, reached on 31 December 2012.IMUX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$95.68 M
-$2.15 M-2.30%
30 September 2024
Summary:
Immunic TTM earnings before interest, taxes, depreciation & amortization is currently -$95.68 million, with the most recent change of -$2.15 million (-2.30%) on 30 September 2024. Over the past year, it has increased by +$4.41 million (+4.41%). IMUX TTM EBITDA is now -4114.98% below its all-time high of -$2.27 million, reached on 30 September 2012.IMUX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMUX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.7% | -9.1% | +4.4% |
| 3 y3 years | -102.5% | -39.8% | -13.8% |
| 5 y5 years | -163.0% | -180.2% | -206.1% |
IMUX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -102.5% | at low | -39.8% | +5.6% | -18.7% | +4.4% |
| 5 y | 5 years | -168.0% | at low | -214.2% | +20.7% | -206.1% | +4.4% |
| alltime | all time | -2388.4% | at low | -8726.1% | +20.7% | -4115.0% | +4.4% |
Immunic EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$25.68 M(+12.7%) | -$95.68 M(+2.3%) |
| June 2024 | - | -$22.78 M(-4.5%) | -$93.53 M(-2.3%) |
| Mar 2024 | - | -$23.86 M(+2.1%) | -$95.75 M(-3.4%) |
| Dec 2023 | -$99.11 M(+14.7%) | -$23.36 M(-0.8%) | -$99.11 M(-1.0%) |
| Sept 2023 | - | -$23.54 M(-5.9%) | -$100.09 M(+3.6%) |
| June 2023 | - | -$25.00 M(-8.2%) | -$96.66 M(+4.8%) |
| Mar 2023 | - | -$27.22 M(+11.8%) | -$92.25 M(+6.7%) |
| Dec 2022 | -$86.44 M(-5.6%) | -$24.34 M(+21.1%) | -$86.44 M(+3.2%) |
| Sept 2022 | - | -$20.10 M(-2.4%) | -$83.78 M(+2.1%) |
| June 2022 | - | -$20.59 M(-3.8%) | -$82.06 M(+1.8%) |
| Mar 2022 | - | -$21.41 M(-1.2%) | -$80.62 M(-12.0%) |
| Dec 2021 | -$91.58 M(+87.2%) | -$21.68 M(+18.0%) | -$91.58 M(+8.9%) |
| Sept 2021 | - | -$18.37 M(-4.1%) | -$84.09 M(+6.1%) |
| June 2021 | - | -$19.16 M(-40.8%) | -$79.22 M(+9.6%) |
| Mar 2021 | - | -$32.37 M(+128.1%) | -$72.28 M(+47.8%) |
| Dec 2020 | -$48.93 M(+32.3%) | -$14.19 M(+5.1%) | -$48.91 M(+14.0%) |
| Sept 2020 | - | -$13.50 M(+10.5%) | -$42.89 M(+11.2%) |
| June 2020 | - | -$12.22 M(+35.7%) | -$38.56 M(-6.7%) |
| Mar 2020 | - | -$9.00 M(+10.1%) | -$41.33 M(+11.7%) |
| Dec 2019 | -$36.98 M(-1.9%) | -$8.17 M(-10.8%) | -$36.98 M(+18.3%) |
| Sept 2019 | - | -$9.17 M(-38.8%) | -$31.26 M(-4.5%) |
| June 2019 | - | -$14.98 M(+221.7%) | -$32.73 M(+7.4%) |
| Mar 2019 | - | -$4.66 M(+89.9%) | -$30.47 M(-24.0%) |
| Dec 2018 | -$37.68 M | -$2.45 M(-77.0%) | -$40.08 M(-23.2%) |
| Sept 2018 | - | -$10.64 M(-16.3%) | -$52.19 M(-3.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | -$12.72 M(-10.9%) | -$53.97 M(+0.7%) |
| Mar 2018 | - | -$14.27 M(-2.0%) | -$53.57 M(+3.7%) |
| Dec 2017 | -$51.66 M(+30.9%) | -$14.56 M(+17.2%) | -$51.66 M(+6.5%) |
| Sept 2017 | - | -$12.42 M(+0.8%) | -$48.52 M(+5.7%) |
| June 2017 | - | -$12.32 M(-0.3%) | -$45.91 M(+7.7%) |
| Mar 2017 | - | -$12.35 M(+8.2%) | -$42.65 M(+8.1%) |
| Dec 2016 | -$39.46 M(-22.3%) | -$11.42 M(+16.3%) | -$39.46 M(+5.1%) |
| Sept 2016 | - | -$9.82 M(+8.4%) | -$37.55 M(-5.5%) |
| June 2016 | - | -$9.06 M(-1.2%) | -$39.74 M(-12.5%) |
| Mar 2016 | - | -$9.16 M(-3.6%) | -$45.43 M(-10.6%) |
| Dec 2015 | -$50.79 M(+3.1%) | -$9.51 M(-20.8%) | -$50.79 M(-7.8%) |
| Sept 2015 | - | -$12.01 M(-18.6%) | -$55.07 M(-0.9%) |
| June 2015 | - | -$14.75 M(+1.6%) | -$55.56 M(+6.4%) |
| Mar 2015 | - | -$14.52 M(+5.4%) | -$52.20 M(+6.0%) |
| Dec 2014 | -$49.26 M(+60.9%) | -$13.78 M(+10.3%) | -$49.25 M(+8.3%) |
| Sept 2014 | - | -$12.50 M(+9.7%) | -$45.49 M(+8.5%) |
| June 2014 | - | -$11.39 M(-1.6%) | -$41.92 M(+12.0%) |
| Mar 2014 | - | -$11.58 M(+15.6%) | -$37.42 M(+6.8%) |
| Dec 2013 | -$30.60 M(+442.9%) | -$10.02 M(+12.1%) | -$35.03 M(+38.4%) |
| Sept 2013 | - | -$8.93 M(+29.7%) | -$25.31 M(+35.7%) |
| June 2013 | - | -$6.89 M(-25.1%) | -$18.64 M(+58.6%) |
| Mar 2013 | - | -$9.20 M(+3059.8%) | -$11.76 M(+359.0%) |
| Dec 2012 | -$5.64 M(-230.2%) | -$291.00 K(-87.2%) | -$2.56 M(+12.8%) |
| Sept 2012 | - | -$2.27 M | -$2.27 M |
| Dec 2011 | $4.33 M | - | - |
FAQ
- What is Immunic annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Immunic?
- What is Immunic annual EBITDA year-on-year change?
- What is Immunic quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Immunic?
- What is Immunic quarterly EBITDA year-on-year change?
- What is Immunic TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Immunic?
- What is Immunic TTM EBITDA year-on-year change?
What is Immunic annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of IMUX is -$99.11 M
What is the all time high annual EBITDA for Immunic?
Immunic all-time high annual earnings before interest, taxes, depreciation & amortization is $4.33 M
What is Immunic annual EBITDA year-on-year change?
Over the past year, IMUX annual earnings before interest, taxes, depreciation & amortization has changed by -$12.67 M (-14.66%)
What is Immunic quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of IMUX is -$25.68 M
What is the all time high quarterly EBITDA for Immunic?
Immunic all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$291.00 K
What is Immunic quarterly EBITDA year-on-year change?
Over the past year, IMUX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$2.15 M (-9.13%)
What is Immunic TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of IMUX is -$95.68 M
What is the all time high TTM EBITDA for Immunic?
Immunic all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.27 M
What is Immunic TTM EBITDA year-on-year change?
Over the past year, IMUX TTM earnings before interest, taxes, depreciation & amortization has changed by +$4.41 M (+4.41%)